Strategic Integration Isolere Bio, now part of Donaldson, presents a compelling channel through which Donaldson’s filtration expertise can be bundled with Isolere’s IsoTag ALPS purification platform to upsell integrated bioprocessing solutions for viral vectors and mRNA manufacturing.

AAV and LV Focus Recent product launches for AAV purification and ongoing interest in lentiviral vector manufacturing collaboration highlight a growth area for sales around downstream purification reagents and scalable ALPS-based separation, targeting gene and cell therapy developers.

Growth Through Partnerships Past and ongoing collaborations with Oxford Biomedica and participation in industry meetings (ASGCT) indicate a proven path for co-developed solutions; pursue co-marketing, joint demonstrations, and alliance-driven pilots to expand access to viral vector manufacturers.

Mid-market Opportunity Financials show modest revenue with clear growth potential; target mid-market biotech firms and contract manufacturers seeking to solve downstream bottlenecks with scalable, single-process purification approaches that reduce steps and time to scale.

Market Positioning Isolere’s unique ALPS technology offers differentiation in affinity and size-based separation; position as a value-add upgrade to existing filtration and chromatography footprints, with emphasis on reducing bottlenecks in AAV, LV, AdV, and mRNA manufacturing pipelines.